Skip to main content
. 2021 Feb 8;13(4):678. doi: 10.3390/cancers13040678
ALC Absolute Lymphocyte Count
APC Antigen-Presenting Cell
ATP Adenosine Triphosphate
BTLA B and T Lymphocyte Attenuator
CALR Calreticulin
CAR Chimeric Antigen Receptor
CTLA4 Cytotoxic T-Lymphocyte-Associated Protein
CRT Chemoradiotherapy
DAMPs Damage-Associated Molecular Patterns
DC Dendritic Cell
HMGB1 High Mobility Group Box 1
HNSCC Head and Neck Squamous Cell Carcinoma
HSP70/90 Heat Shock Proteins 70/90
ICD Immunogenic Cell Death
ICI Immune Checkpoint Inhibitor
irAEs Immune-related Adverse Events
LA Locally Advanced
LAG3 Lymphocyte Activation Gene 3
MDSC Myeloid-Derived Suppressor Cell
MHC-1 Major Histocompatibility Complex class 1
NSCLC Non-Small Cell Lung Carcinoma
OS Overall Survival
PD-1 Programmed cell death 1
PD-L1 Programmed death-ligand 1
ROS Reactive Oxygen Species
PFS Progression Free Survival
RCC Renal Cell Carcinoma
RT Radiation Therapy
SBRT Stereotactic Body Radiation Therapy
TGFβ Transforming Growth Factor Beta
TIGIT T cell Immunoglobulin and ITIM domain
TNFα Tumor Necrosis Factor Alpha
Treg Regulatory T cells
TREX1 Three prime Repair Exonuclease 1
TRAIL TNF-related Apoptosis-Inducing Ligand
VISTA V-Domain Ig Suppressor of T cell Activation